Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 2/20 | 0.42 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 10/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.32 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17471261 | 0.81 | GRIA1 (0.50) | GRIA1GRIA3P2RX7GRIA2GRIA4 | |
| SCHEMBL3179817 | 0.79 | GRIA1 (0.44) | GRIA1GRIA3P2RX7GRIA2GRIA4 | |
| SCHEMBL3189524 | 0.71 | GRIA1 (0.43) | GRIA1GRIA3GRIA2GRIA4L3MBTL1 | |
| SCHEMBL8237746 | 0.68 | LMNA (0.44) | ALDH1A1L3MBTL1 | |
| SCHEMBL23869397 | 0.67 | P2RX7 (0.48) | P2RX7ALDH1A1L3MBTL1 | |
| SCHEMBL5451073 | 0.66 | GRIA1 (0.60) | GRIA1GRIA3RAB9AGRIA2GRIA4 | |
| SCHEMBL17472045 | 0.66 | GRIA1 (0.44) | GRIA1GRIA3GRIA2GRIA4ALDH1A1 | |
| SCHEMBL9057892 | 0.65 | LMNA (0.31) | — | |
| SCHEMBL3179822 | 0.65 | NOS2 (0.41) | GRIA1GRIA3 | |
| SCHEMBL3170099 | 0.65 | GRIA1 (0.46) | GRIA1GRIA3GRIA2GRIA4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11420934-B2 | PPAR agonists | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2022-08-23 | — | — | US | disclosed |
| US-20200190019-A1 | PPAR AGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11420934-B2 | PPAR agonists | PPARG, PPARD, PPARA | GRIA1 762/4885GRIA3 947/4885P2RX7 748/4885 |
| US-20200190019-A1 | PPAR AGONISTS | PPARG, PPARD, PPARA | GRIA1 762/4885GRIA3 947/4885P2RX7 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.